Stocks · News reference
Silence Therapeutics Says Phase 2 SANRECO Trial Of Divesiran In Polycythemia Vera Met Primary Endpoint, 88% Response Rate vs. 19% For Placebo; Phase 3 Seen Starting 1H 2027
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 10, 2026, 11:33 AM
- Checked
- Aug 10, 2026, 11:33 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Morgan Stanley Maintains Overweight on Silence Therapeutics, Raises Price Target to $32
Morgan Stanley analyst Michael Ulz maintains Silence Therapeutics (NASDAQ:SLN) with a Overweight and raises the price target from $25 to $32.
Read original at benzingaSilence Therapeutics Announces Commencement Of Approximately $150M Underwritten Public Offering Of American Depositary Shares
Read original at benzingaSilence Therapeutics Says Blood Cancer Trial Delivers 'Best-Case Outcome'
Silence Therapeutics reports positive Phase 2 SANRECO trial data for divesiran in polycythemia vera. Phase 3 trial planned for 1H 2027.
Read original at benzinga